- Startseite
- Forschung
- Arbeitsgruppen & Labore
- AG Angewandte Ethik in der translationalen Krebsforschung
- Research Group of Applied Ethics in Translational Oncology-e
- AG Ambulante Infektiologie
- AG Angewandte Ethik in der translationalen Krebsforschung
- AG Intravaskuläre Infektionen und Knocheninfektionen
- AG Klinische Antiinfektiva-Entwicklung und Epidemiologie seltener Infektionen
- AG Klinische Mikrobiomforschung
- AG Kohorten in der Infektionsforschung
- AG Onkologische Bewegungsmedizin
- AG Psychoonkologische Versorgungsforschung
- AG Translationale Tumorgenetik und Immuntherapie
- AG T-Zellen und Genomtechnik
- CLL-Biobank
- Computational Biomedicine & Bioinformatics Group
- Gastrointestinal Cancer Group Cologne
- Krebstherapie und Molekulare Bildgebung
- Labor für Mikromilieu und Therapie Maligner Lymphome
- Labor für molekulare Hämatologie und Onkologie
- Labor für molekulare Immunologie
- Labor für molekulare Pathogenese der CLL
- Labor für präklinische Arzneimittel-Testung
- Labor für regulatorische Netzwerke reifzelliger T-Zell Leukämien
- Labor für translationale Infektionsimmunologie
- Labor für Tumorgenetik und Zellbiologie
- Laboratory for tumor-host interdependence
- Translational Immune-Oncology
- Translationale Krebsforschungsgruppe
- Translational Research Unit – Infectious Diseases
- Nachwuchsprogramme in der Onkologischen Forschung
- HEnRY
Research Group of Applied Ethics in Translational Oncology
Ethics is currently in a dynamic phase of progressing towards clinical application: strategic processes are underway in all affected areas of research. Furthermore, at the community level clinical ethics structures and practical procedures are being improved under consideration of oncology experts' recommendations.
The complex questions of clinical ethics, science, society and the economy need to be dealt with holistically, from the principles of ethics to their application. We are working on finding solutions, translating them into clinical practice and implementing them into care as system competences and compliance systems in medicine. Our work encompasses the following areas:
- Innovative oncology in personalized medicine
- Indicated and success-critical diagnostics
- Integrated care, as reflected in clinical ethics
- New concepts for providing information to oncology patients
- Translation into clinical practice to achieve individualised and precise treatment in oncology with the help of applied ethics
- New generations of compact advisory systems in clinical care: advance care planning, advance research planning, shared decision making and supported decision making
A sharpening and clarification of the application of ethics, in particular at the level of applied clinical research, should further increase the scientific and strategic formative capacity of clinical ethics with regard to urgent economic issues. At the level of the CIO community, the Director of the CIO and the Steering Committee, as the higher advisory and voting committee, perform prominent functions in guiding practical ethics from a clinical-scientific perspective and in defining the future fields to be developed. There is agreement that the clinical research fields and boards established with practical ethics can serve as a communication and strategy platform.
In the applied research fields of practical ethics, a range of practice-related procedures are being developed that will emphasise the following new features: promotion of innovation; translation into clinical practice; and formation of crucially important partnerships (with science and industry, among others). In the future, a decided focus should be placed on establishing early strategic alliances between complementary business partners. To promote innovation, through targeted participation and increased transfer of knowledge in these newly created strategic alliances, we will also expand the exchange with clinical ethics – in a mutual dialogue between care and research – into two strategic fields:
- Strategic clinical ethics and innovation (whereby innovative concepts
will be chosen wisely) - Strategic development partnerships and new formats in business
collaborations with complementary content
In particular, certain ethical questions in the field of precision oncology and economic issues in solidarity-based health care Systems should be at the centre of this newly formed field
- Barnikol UB, Michael N
Advance Care Planning in der Psychiatrie
Rhein. Ärztebl. 2021. Heft 10/2021 - Abdullayev N, Maus V, Behme D, Barnikol UB, Kutschke S, Stocker A, Goertz L Celik E, Zaeske C, Borggrefe J Schlamann M, Liebig T, Kabbasch C, Mpotsaris A.
True first-pass effect in basilar artery occlusions: First-pass complete reperfusion improves clinical outcome in stroke thrombectomy patients
Journal of Clinical Neuroscience Volume 89, July 2021, Pages 33-38, online first April 29. 2021 - Wiltfang J, Esselmann H, Barnikol UB
The Use of Artificial Intelligence in Alzheimer's Disease - Personalized Diagnostics and Therapy
Psychiatr Prax. 2021 Mar;48(S 01):S31-S36 - Fehn K, U Klitsch W, Barnikol UB
Compliance Systeme im Gesundheitswesen
Gesundheit Gesellschaft und Kultur (1) (2021). - Barnikol UB, Mpotsaris A, Wiltfang J.
On Indicated Predictive Medicine - How much Information does the Patient need?
Interdiszipl. Med. (2) 14 (2019). - Barnikol UB, Mpotsaris A, Wiltfang J.
Zukunftsplattform Applied Ethics for Precision Oncology of Cologne (AEPO)
Interdiszipl. Med. (8) 17 (2018). - Barnikol UB & Wiltfang J.
Willingness to pay or willingness to accept?
Interdiszipl. Med. (7) 11 (2018). - Barnikol UB, Beck S, Birnbacher D, Fangerau H, Langenberg U, Schulenburg D, Steinert S.
Prädiktive Medizin- eine rechtliche Perspektive.
MedR 34 Nov092017 first online doi:10.1007/s00350-016-4399-6 October 2016, Volume 34, Issue 10, pp 753–757 (2016). - Tass PA, Barnikol UB, Hauptmann C, Haroud K, Roulet JC, Schnell U.
Device and method for visual stimulation.
Assignee: Forschungszentrum Juelich GmbH (Juelich, DE) Universitaet zu Koeln
(Cologne,DE) United States Patent 9.302.069 April 5 (2016) Family ID: 1000001752184 Appl. No.: 12/875,619 Assignees: Forschungszentrum Juelich GmbH, ANM Adaptive Neuromodulation GmbH, Universitaet zu Koeln. Type: A (2016). - Barnikol UB, Beck S, Birnbacher D, Fangerau H.
Advance Care Planning - eine dynamische Form der Patientenverfügung.
Ärztezeitung 17. August 2015 online (2015). - Barnikol UB, Fangerau H, Beck S, Birnbacher D.
Die Achtung vor der Menschenwürde in der
Psychiatrie, NeuroMarginal in Neuroaktuell 11 (2015). - Maier W & Barnikol UB.
Die Indikation für autonomieersetzende Interventionen bei psychisch kranken Menschen.
In: Medizinische Indikationen. Ärztliche, ethische und rechtliche Perspektiven. Grundlagen und Praxis Andrea Dörries / Volker Lipp (Hrsg.) Kohlhammer Verlag Stuttgart, 1. Auflage S. 199-211 (2015). - Birnbacher D, Klitzsch W, Langenberg U, Barnikol UB.
Dealing with dementia patients: Jointly responsible for decisions.
DtschArztebl 2015; 112(12): A-514 / B-438 / C-426. (2015). - Vollmann J, Walter H, Barnikol UB, Finzen A, Gather J, Gerlinger G, Heberlein A, Heinz A, Helmchen H, Lieb K, Maier W, Müller JL, Müller S, Pollmächer T, Saß H, Schramme T, Seidel M.
Achtung der Selbstbestimmung bei Anwendung von Zwang bei der Behandlung psychisch erkrankter Menschen. Eine ethische Stellungnahme der DGPPN/Task Force "Ethik in Psychiatrie und Psychotherapie" der DGPPN.
Nervenarzt 85(11): 1419-1431 (2014). - Heinrichs J-H, Langenberg U, Klitzsch W, Barnikol UB.
Neuropsychiatric Grace Period-Between Symptom and Diagnosis.
Nervenheilkunde 4, 237 - 245 (2012).